Ainos (AIMD) Competitors $3.46 -0.17 (-4.68%) As of 11:33 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AIMD vs. MGX, OSTX, PRLD, ADVM, ALGS, ELYM, ANL, ABVC, GNTA, and IMMXShould you be buying Ainos stock or one of its competitors? The main competitors of Ainos include Metagenomi (MGX), OS Therapies (OSTX), Prelude Therapeutics (PRLD), Adverum Biotechnologies (ADVM), Aligos Therapeutics (ALGS), Eliem Therapeutics (ELYM), Adlai Nortye (ANL), ABVC BioPharma (ABVC), Genenta Science (GNTA), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry. Ainos vs. Its Competitors Metagenomi OS Therapies Prelude Therapeutics Adverum Biotechnologies Aligos Therapeutics Eliem Therapeutics Adlai Nortye ABVC BioPharma Genenta Science Immix Biopharma Metagenomi (NASDAQ:MGX) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk. Which has more volatility & risk, MGX or AIMD? Metagenomi has a beta of -0.17, meaning that its share price is 117% less volatile than the S&P 500. Comparatively, Ainos has a beta of 2.25, meaning that its share price is 125% more volatile than the S&P 500. Do analysts rate MGX or AIMD? Metagenomi presently has a consensus target price of $10.00, suggesting a potential upside of 444.96%. Given Metagenomi's stronger consensus rating and higher possible upside, equities analysts plainly believe Metagenomi is more favorable than Ainos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Ainos 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is MGX or AIMD more profitable? Ainos has a net margin of 0.00% compared to Metagenomi's net margin of -257.99%. Metagenomi's return on equity of -37.84% beat Ainos' return on equity.Company Net Margins Return on Equity Return on Assets Metagenomi-257.99% -37.84% -27.15% Ainos N/A -108.25%-56.94% Which has higher earnings and valuation, MGX or AIMD? Ainos has lower revenue, but higher earnings than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetagenomi$52.29M1.32-$78.06M-$2.36-0.78Ainos$20K806.18-$14.86M-$4.99-0.69 Does the media refer more to MGX or AIMD? In the previous week, Ainos had 1 more articles in the media than Metagenomi. MarketBeat recorded 2 mentions for Ainos and 1 mentions for Metagenomi. Metagenomi's average media sentiment score of 1.76 beat Ainos' score of -0.01 indicating that Metagenomi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ainos 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryMetagenomi beats Ainos on 8 of the 14 factors compared between the two stocks. Get Ainos News Delivered to You Automatically Sign up to receive the latest news and ratings for AIMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AIMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIMD vs. The Competition Export to ExcelMetricAinosMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.12M$2.64B$5.79B$9.92BDividend YieldN/A49.35%6.67%4.51%P/E Ratio-0.6923.2575.7326.67Price / Sales806.18740.86556.54122.11Price / CashN/A169.7737.1158.92Price / Book0.635.4411.296.07Net Income-$14.86M$32.95M$3.29B$266.51M7 Day Performance-9.42%1.88%0.62%-0.04%1 Month Performance48.50%6.88%6.94%3.84%1 Year Performance21.40%0.29%57.33%23.68% Ainos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMDAinos0.4283 of 5 stars$3.46-4.7%N/A+19.0%$16.12M$20K-0.6940Short Interest ↑Gap DownMGXMetagenomi2.5976 of 5 stars$1.82flat$10.00+449.5%-36.4%$68.31M$52.29M-0.77236Positive NewsOSTXOS Therapies2.1306 of 5 stars$2.13-4.3%$18.00+747.1%-49.3%$67.56MN/A-2.70N/AAnalyst ForecastPRLDPrelude Therapeutics3.6496 of 5 stars$1.19+4.9%$4.00+237.6%-78.0%$67.07M$7M-0.72120Positive NewsADVMAdverum Biotechnologies3.5701 of 5 stars$3.20+5.1%$19.75+518.2%-53.2%$66.94M$1M-0.41190ALGSAligos Therapeutics4.2897 of 5 stars$10.70+0.7%$50.00+367.4%-8.5%$66.76M$3.94M-0.5590ELYMEliem TherapeuticsN/A$2.23-3.0%N/A-66.3%$66.35MN/A-4.219ANLAdlai Nortye1.4075 of 5 stars$1.79+5.9%$9.00+402.8%-37.1%$66.05M$5M0.00127News CoverageShort Interest ↑Gap UpABVCABVC BioPharma0.1719 of 5 stars$2.74+0.4%N/A+312.7%$65.56M$510K-16.3830GNTAGenenta Science2.7696 of 5 stars$3.57+1.0%$25.00+601.3%-13.6%$65.20MN/A0.007Gap UpIMMXImmix Biopharma3.3904 of 5 stars$2.25-1.3%$7.00+211.1%+8.8%$64.90MN/A-2.929Short Interest ↓ Related Companies and Tools Related Companies MGX Competitors OSTX Competitors PRLD Competitors ADVM Competitors ALGS Competitors ELYM Competitors ANL Competitors ABVC Competitors GNTA Competitors IMMX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AIMD) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ainos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ainos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AIMD Stock Alerts